Toward fully exploiting the therapeutic potential of marketed pharmaceuticals: the use of octreotide and chloroquine in oncology

References

• PerwitasariOBakreATompkinsSMTrippRAsiRNA genome screening approaches to therapeutic drug repositioningPharmaceuticals20136212416024275945
   PubMedGoogle Scholar
• CorbettAWilliamsGBallardCDrug repositioning: an opportunity to develop novel treatments for Alzheimer’s diseasePharmaceuticals20136101304132124275851
   PubMedGoogle Scholar
• BatchuRBGruzdynOVBryantCSRitonavir-mediated induction of apoptosis in pancreatic cancer occurs via the RB/E2F-1 and AKT pathwaysPharmaceuticals201471465724451403
   PubMedGoogle Scholar
• ShimJSLiuJORecent advances in drug repositioning for the discovery of new anticancer drugsInt J Biol Sci201410765466325013375
   PubMed Web of Science ®Google Scholar
• ShameerKReadheadBDudleyJTComputational and experimental advances in drug repositioning for accelerated therapeutic stratificationCurr Top Med Chem201515152025579574
   PubMed Web of Science ®Google Scholar
• WickWKesslerTDrug repositioning meets precision in glioblastomaClin Cancer Res201824225625829133572
   PubMed Web of Science ®Google Scholar
• KimCHLeblancPKimKS4-amino-7-chloroquinoline derivatives for treating Parkinson’s disease: implications for drug discoveryExpert Opin Drug Discov201611433734126924734
   PubMed Web of Science ®Google Scholar
• FreedmanASteinbergVLChloroquine in rheumatoid arthritis; a double blindfold trial of treatment for one yearAnn Rheum Dis196019324325013701598
   PubMed Web of Science ®Google Scholar
• PatelJCChloroquine in the treatment of amoebic liver abscessBr Med J19531481481181313032509
   PubMedGoogle Scholar
• LeeSJSilvermanEBargmanJMThe role of antimalarial agents in the treatment of SLE and lupus nephritisNat Rev Nephrol201171271872922009248
   PubMed Web of Science ®Google Scholar
• PapanagnouPBaltopoulosPTsironiMMarketed nonsteroidal anti-inflammatory agents, antihypertensives, and human immunodeficiency virus protease inhibitors: as-yet-unused weapons of the oncologists’ arsenalTher Clin Risk Manag20151180781926056460
   PubMed Web of Science ®Google Scholar
• PapanagnouPStivarouTTsironiMUnexploited antineoplastic effects of commercially available anti-diabetic drugsPharmaceuticals20169224
   Google Scholar
• PapanagnouPStivarouTPapageorgiouIPapadopoulosGPappasAMarketed drugs used for the management of hypercholesterolemia as anticancer armamentOncoTargets and Therapy2017104393441128932124
   PubMed Web of Science ®Google Scholar
• TangCLeiHZhangJMontelukast inhibits hypoxia inducible factor-1alpha translation in prostate cancer cellsCancer Biology & Therapy201817
   Web of Science ®Google Scholar
• ShiTTYuXXYanLJXiaoHTResearch progress of hydroxychloroquine and autophagy inhibitors on cancerCancer Chemother Pharmacol201779228729427889812
   PubMed Web of Science ®Google Scholar
• ChudeCIAmaravadiRKTargeting autophagy in cancer: update on clinical trials and novel inhibitorsInt J Mol Sci2017186E127928621712
   PubMed Web of Science ®Google Scholar
• HallEARamseyJEPengZNovel organometallic chloroquine derivative inhibits tumor growthJ Cell Biochem201811975921593329575007
   PubMed Web of Science ®Google Scholar
• SolomonVRLeeHChloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapiesEur J Pharmacol20096251–322023319836374
   PubMed Web of Science ®Google Scholar
• ZhangYLiaoZZhangLJXiaoHTThe utility of chloroquine in cancer therapyCurr Med Res Opin20153151009101325734693
   PubMed Web of Science ®Google Scholar
• PascoloSTime to use a dose of Chloroquine as an adjuvant to anticancer chemotherapiesEur J Pharmacol201677113914426687632
   PubMed Web of Science ®Google Scholar
• BorbathILeclercqIASempouxCAbarca-QuinonesJDesaegerCHorsmansYEfficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in ratsChem Biol Interact2010183123824819874807
   PubMed Web of Science ®Google Scholar
• GraillonTRomanoDDefillesCPasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitroOncotarget2017833553615537328903425
   PubMedGoogle Scholar
• KhandelwalDKhadgawatRMukundASuriAAcromegaly with no pituitary adenoma and no evidence of ectopic sourceIndian J Endocrinol Metab201115Suppl 3S250S25222029034
   PubMedGoogle Scholar
• LavrentakiAPaluzziAWassJAKaravitakiNEpidemiology of acromegaly: review of population studiesPituitary20172014927743174
   PubMed Web of Science ®Google Scholar
• HoflandLJLambertsSWSomatostatin receptors and disease: role of receptor subtypesBaillieres Clin Endocrinol Metab19961011631768734455
   PubMedGoogle Scholar
• FougnerSLBollerslevJLatifFLow levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatmentJ Clin Endocrinol Metab20089341211121618230656
   PubMed Web of Science ®Google Scholar
• NeildPJEvansDFCastilloFDEffect of octreotide on small intestinal motility in HIV-infected patients with chronic refractory diarrheaDig Dis Sci200146122636264211768253
   PubMed Web of Science ®Google Scholar
• CorbouldACampbellJEfficacy of octreotide but not long-acting somatostatin analogue for severe refractory diabetic diarrhoeaDiabet Med200926882882919709156
   PubMed Web of Science ®Google Scholar
• BelloSORahamimJHigh-dose intravenous octreotide is safe and may be superior to surgery in managing severe postesophagectomy chylothorax in high-risk patientsAnn Thorac Surg2015100129729926140770
   PubMed Web of Science ®Google Scholar
• ArnouxJBVerkarreVSaint-MartinCCongenital hyperinsulinism: current trends in diagnosis and therapyOrphanet J Rare Dis2011616321967988
   PubMedGoogle Scholar
• HosokawaYKawakitaRYokoyaSEfficacy and safety of octreotide for the treatment of congenital hyperinsulinism: a prospective, open-label clinical trial and an observational study in Japan using a nationwide registryEndocr J201764986788028701683
   PubMed Web of Science ®Google Scholar
• JungSYRohanTStricklerHGenetic variants and traits related to insulin-like growth factor-I and insulin resistance and their interaction with lifestyles on postmenopausal colorectal cancer riskPLoS One20171210e018629629023587
   PubMed Web of Science ®Google Scholar
• BarbieriFBajettoAPattarozziAPeptide receptor targeting in cancer: the somatostatin paradigmInt J Pept201320132120
   Google Scholar
• PeverelliEGiardinoETreppiediDA novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitmentInt J Cancer201814291842185229226331
   PubMed Web of Science ®Google Scholar
• DavisMPNounehCModern management of cancer-related intestinal obstructionCurr Oncol Rep20002434335011122863
   PubMedGoogle Scholar
• RipamontiCPanzeriCGroffLGaleazziGBoffiRThe role of somatostatin and octreotide in bowel obstruction: pre-clinical and clinical resultsTumori200187119
   PubMed Web of Science ®Google Scholar
• PokuriVKFongMKIyerROctreotide and lanreotide in gastroentero-pancreatic neuroendocrine tumorsCurr Oncol Rep2016181726743514
   PubMed Web of Science ®Google Scholar
• LiYDuanZTianYLiuZWangQA novel perspective and approach to intestinal octreotide absorption: sinomenine-mediated reversible tight junction opening and its molecular mechanismInt J Mol Sci2013146128731289223787475
   PubMed Web of Science ®Google Scholar
• GrimbergASomatostatin and cancer: applying endocrinology to oncologyCancer Biol Ther20043873173315326367
   PubMed Web of Science ®Google Scholar
• MuscarellaLAD’AlessandroVLa TorreAGene expression of somatostatin receptor subtypes SSTR2a, SSTR3 and SSTR5 in peripheral blood of neuroendocrine lung cancer affected patientsCell Oncol2011345435441
   Web of Science ®Google Scholar
• SidérisLDubéPRinkeAAntitumor effects of somatostatin analogs in neuroendocrine tumorsOncologist201217674775522628056
   PubMed Web of Science ®Google Scholar
• MehtaSde ReuverPRGillPSomatostatin receptor SSTR-2a expression is a stronger predictor for survival than Ki-67 in pancreatic neuroendocrine tumorsMedicine20159440e128126447992
   PubMed Web of Science ®Google Scholar
• PhanATHalperinDMChanJAPazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 studyLancet Oncol201516669570325956795
   PubMed Web of Science ®Google Scholar
• MaxwellJEHoweJRImaging in neuroendocrine tumors: an update for the clinicianInt J Endocr Oncol20152215916826257863
   PubMedGoogle Scholar
• HamiditabarMAliMRoysJPeptide receptor radionuclide therapy with 177Lu-octreotate in patients with somatostatin receptor expressing neuroendocrine tumors: six years’ assessmentClin Nucl Med201742643644328263217
   PubMed Web of Science ®Google Scholar
• YauHKinaanMQuinnSLMoraitisAGOctreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectivesBiologics20171111512229255345
   PubMed Web of Science ®Google Scholar
• AokiTMotoiFSakataNSomatostatin analog inhibits the growth of insulinoma cells by p27-mediated G1 cell cycle arrestPancreas201443572072924694834
   PubMed Web of Science ®Google Scholar
• Ben-ShlomoAMelmedSPituitary somatostatin receptor signalingTrends Endocrinol Metab201021312313320149677
   PubMed Web of Science ®Google Scholar
• LehaneAMHaywardRSalibaKJKirkKA verapamil-sensitive chloroquine-associated H+ leak from the digestive vacuole in chloroquine-resistant malaria parasitesJ Cell Sci2008121Pt 101624163218445688
   PubMed Web of Science ®Google Scholar
• CoronadoLMNadovichCTSpadaforaCMalarial hemozoin: from target to toolBiochim Biophys Acta2014184062032204124556123
   PubMed Web of Science ®Google Scholar
• Al-BariMAChloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseasesJ Antimicrob Chemother20157061608162125693996
   PubMed Web of Science ®Google Scholar
• RebeccaVWAmaravadiRKEmerging strategies to effectively target autophagy in cancerOncogene201635111125893285
   PubMed Web of Science ®Google Scholar
• Martinez-OutschoornUEPavlidesSWhitaker-MenezesDTumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitorsCell Cycle20109122423243320562526
   PubMed Web of Science ®Google Scholar
• McAfeeQZhangZSamantaAAutophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiencyProc Natl Acad Sci U S A2012109218253825822566612
   PubMed Web of Science ®Google Scholar
• YangAKimmelmanACInhibition of autophagy attenuates pancreatic cancer growth independent of TP53/TRP53 statusAutophagy20141091683168425046107
   PubMed Web of Science ®Google Scholar
• GaoSYuBPLiYDongWGLuoHSAntiproliferative effect of octreotide on gastric cancer cells mediated by inhibition of Akt/PKB and telomeraseWorld J Gastroenterol20039102362236514562414
   PubMed Web of Science ®Google Scholar
• WangCTangCInhibition of human gastric cancer metastasis by ocreotide in vitro and in vivoZhonghua Yi Xue Za Zhi2002821192211953120
   PubMedGoogle Scholar
• WangLHuangXChaiYZouLChedraweMDingYOctreotide inhibits the proliferation of gastric cancer cells through P300-HAT activity and the interaction of ZAC and P300Oncol Rep20173742041204828260048
   PubMed Web of Science ®Google Scholar
• HoffmannABarzTSpenglerDMultitasking C2H2 zinc fingers link Zac DNA binding to coordinated regulation of p300-histone acetyltransferase activityMol Cell Biol200626145544555716809786
   PubMed Web of Science ®Google Scholar
• LiSCMartijnCCuiTThe somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cellsPLoS One2012710e4841123119007
   PubMed Web of Science ®Google Scholar
• WangSBaoZLiangQMOctreotide stimulates somatostatin receptor-induced apoptosis of SW480 colon cancer cells by activation of glycogen synthase kinase-3β, A Wnt/β-catenin pathway modulatorHepatogastroenterology2013601271639164624634935
   PubMedGoogle Scholar
• ChenJSLiangQMLiHSYangJWangSLongJWOctreotide inhibits growth of colonic cancer SW480 cells by modulating the Wnt/P-catenin pathwayPharmazie200964212613119320286
   PubMed Web of Science ®Google Scholar
• AyiomamitisGDNotasGZaravinosAEffects of octreotide and insulin on colon cancer cellular proliferation and correlation with hTERT activityOncoscience20141645746725594044
   PubMedGoogle Scholar
• LiuHLHuoLWangLOctreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cellsActa Pharmacol Sin200425101380138615456543
   PubMed Web of Science ®Google Scholar
• MaQMengLQLiuJCOctreotide induces apoptosis of human hepatoma cells by the mechanism of facilitating the Fas/FasL gene expression thereinZhonghua Yi Xue Za Zhi2008881071671818642777
   PubMedGoogle Scholar
• DaviesNKynastonHYatesJOctreotide inhibits the growth and development of three types of experimental liver metastasesBr J Surg19958268408437627527
   PubMed Web of Science ®Google Scholar
• JiaWDXuGLWangWA somatostatin analogue, octreotide, inhibits the occurrence of second primary tumors and lung metastasis after resection of hepatocellular carcinoma in miceTohoku J Exp Med2009218215516019478472
   PubMed Web of Science ®Google Scholar
• TangXTakekoshiSItohJSomatostatin analogue inhibits the mobility of prostate carcinoma cells: a new therapeutic method for advanced prostate carcinomaInt J Oncol20103751077108320878055
   PubMed Web of Science ®Google Scholar
• HennigsJKMüllerJAdamMLoss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapsePLoS One201497e10046925010045
   PubMed Web of Science ®Google Scholar
• ShenYRenMShiYZhangYCaiYOctreotide enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitroExp Ther Med2011261171117622977639
   PubMed Web of Science ®Google Scholar
• ShenYZhangXYChenXRenMLCaiYLOctreotide reverses the resistance of A2780/Pacliaxel ovarian cancer cell line to paclitaxel chemotherapy in vitroJ Cancer Res Ther201612265766227461627
   PubMed Web of Science ®Google Scholar
• MorenoAAkcakanatAMunsellMFSoniAYaoJCMeric- BernstamFAntitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumorsEndocr Relat Cancer200815125726618310292
   PubMed Web of Science ®Google Scholar
• HoeltingTDuhQYClarkOHHerfarthCSomatostatin analog octreotide inhibits the growth of differentiated thyroid cancer cells in vitro, but not in vivoJ Clin Endocrinol Metab1996817263826418675590
   PubMed Web of Science ®Google Scholar
• DalezisPGeromichalosGDVoyatziSCombinational effect of topotecan and octreotide on murine leukemia cells in vivo and in vitroJ BUON200611332332717309157
   PubMedGoogle Scholar
• ChoiJHYoonJSWonYWParkBBLeeYYChloroquine enhances the chemotherapeutic activity of 5-fluorouracil in a colon cancer cell line via cell cycle alterationAPMIS2012120759760422716215
   PubMed Web of Science ®Google Scholar
• ZhengYZhaoYLDengXChloroquine inhibits colon cancer cell growth in vitro and tumor growth in vivo via induction of apoptosisCancer Invest200927328629219194831
   PubMed Web of Science ®Google Scholar
• ZeilhoferHUMollenhauerJBruneKSelective growth inhibition of ductal pancreatic adenocarcinoma cells by the lysosomotropic agent chloroquineCancer Lett198944161662537140
   PubMed Web of Science ®Google Scholar
• MonmaHIidaYMoritaniTChloroquine augments TRAIL-induced apoptosis and induces G2/M phase arrest in human pancreatic cancer cellsPLoS One2018133e019399029513749
   PubMed Web of Science ®Google Scholar
• FrieboesHBHuangJSYinWCMcNallyLRChloroquine-mediated cell death in metastatic pancreatic adenocarcinoma through inhibition of autophagyJOP201415218919724618445
   PubMedGoogle Scholar
• SongJQuZGuoXHypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cellsAutophagy2009581131114419786832
   PubMed Web of Science ®Google Scholar
• GaoLSongJRZhangJWChloroquine promotes the anticancer effect of TACE in a rabbit VX2 liver tumor modelInt J Biol Sci20139432233023569437
   PubMed Web of Science ®Google Scholar
• AqbiHFTyutyunyk-MasseyLKeimRCAutophagy-deficient breast cancer shows early tumor recurrence and escape from dormancyOncotarget2018931221132212229774126
   PubMedGoogle Scholar
• HuTLiPLuoZChloroquine inhibits hepatocellular carcinoma cell growth in vitro and in vivoOncol Rep2016351434926530158
   PubMed Web of Science ®Google Scholar
• LamoureuxFZoubeidiADual inhibition of autophagy and the AKT pathway in prostate cancerAutophagy2013971119112023670050
   PubMed Web of Science ®Google Scholar
• WuZChangPCYangJCAutophagy blockade sensitizes prostate cancer cells towards Src family kinase inhibitorsGenes Cancer201011404920811583
   PubMedGoogle Scholar
• FukudaTOdaKWada-HiraikeOAutophagy inhibition augments resveratrol-induced apoptosis in Ishikawa endometrial cancer cellsOncol Lett20161242560256627698828
   PubMed Web of Science ®Google Scholar
• FukudaTOdaKWada-HiraikeOThe anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibitionGynecol Oncol2015137353854525842161
   PubMed Web of Science ®Google Scholar
• FanCWangWZhaoBZhangSMiaoJChloroquine inhibits cell growth and induces cell death in A549 lung cancer cellsBioorg Med Chem20061493218322216413786
   PubMed Web of Science ®Google Scholar
• LiuLHanCYuHChloroquine inhibits cell growth in human A549 lung cancer cells by blocking autophagy and inducing mitochondrialmediated apoptosisOncol Rep20183962807281629658606
   PubMed Web of Science ®Google Scholar
• Avniel-PolakSLeibowitzGDovinerVGrossDJGrozinsky-GlasbergSCombining chloroquine with RAD001 inhibits tumor growth in a NEN mouse modelEndocr Relat Cancer201825667768629636368
   PubMed Web of Science ®Google Scholar
• Avniel-PolakSLeibowitzGRiahiYGlaserBGrossDJGrozinsky-GlasbergSAbrogation of autophagy by chloroquine alone or in combination with mTOR inhibitors induces apoptosis in neuroendocrine tumor cellsNeuroendocrinology2016103672473726619207
   PubMed Web of Science ®Google Scholar
• AveicSPantileMSeydelACombating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cellsOncotarget2016755646566326735175
   PubMedGoogle Scholar
• RoyLOPoirierMBFortinDChloroquine inhibits the malignant phenotype of glioblastoma partially by suppressing TGF-betaInvest New Drugs20153351020103126271735
   PubMed Web of Science ®Google Scholar
• SpcHKuoJSChiangHCTemozolomide, sirolimus and chloroquine is a new therapeutic combination that synergizes to disrupt lysosomal function and cholesterol homeostasis in GBM cellsOncotarget2018966883689629467937
   PubMedGoogle Scholar
• EggerMEHuangJSYinWMcMastersKMMcNallyLRInhibition of autophagy with chloroquine is effective in melanomaJ Surg Res2013184127428123706562
   PubMed Web of Science ®Google Scholar
• MgrditchianTArakelianTPaggettiJTargeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent mannerProc Natl Acad Sci U S A201711444E9271E927929078276
   PubMed Web of Science ®Google Scholar
• JiangPDZhaoYLShiWCell growth inhibition, G2/M cell cycle arrest, and apoptosis induced by chloroquine in human breast cancer cell line Bcap-37Cell Physiol Biochem2008225–643144019088425
   PubMed Web of Science ®Google Scholar
• YangWHosfordSRTraphagenNAAutophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancerFaseb J20183231222123529127189
   PubMed Web of Science ®Google Scholar
• ChoiDSBlancoEKimYSChloroquine eliminates cancer stem cells through deregulation of Jak2 and DNMT1Stem Cells20143292309232324809620
   PubMed Web of Science ®Google Scholar
• LiangDHChoiDSEnsorJEKaipparettuBABassBLChangJCThe autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repairCancer Lett2016376224925827060208
   PubMed Web of Science ®Google Scholar
• MaycottePAryalSCummingsCTThorburnJMorganMJThorburnAChloroquine sensitizes breast cancer cells to chemotherapy independent of autophagyAutophagy20128220021222252008
   PubMed Web of Science ®Google Scholar
• BurikhanovRHebbarNNoothiSKChloroquine-inducible Par-4 secretion is essential for tumor cell apoptosis and inhibition of metastasisCell Rep201718250851928076793
   PubMed Web of Science ®Google Scholar
• LiQYuanDMMaLHChloroquine inhibits tumor growth and angiogenesis in malignant pleural effusionTumour Biol20161624916258
   Google Scholar
• DahmenRPKochADenkhausDDeletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomasCancer Res200161197039704311585731
   PubMed Web of Science ®Google Scholar
• LuoWZouHJinLAxin contains three separable domains that confer intramolecular, homodimeric, and heterodimeric interactions involved in distinct functionsJ Biol Chem200528065054506015579909
   PubMed Web of Science ®Google Scholar
• CredleJJGeorgeJLWillsJGSK-3β dysregulation contributes to parkinson’s-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synucleinCell Death Differ201522583885125394490
   PubMed Web of Science ®Google Scholar
• SpinkKEPolakisPWeisWIStructural basis of the Axin-adenomatous polyposis coli interactionEmbo J200019102270227910811618
   PubMed Web of Science ®Google Scholar
• WuZQBrabletzTFearonECanonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activityProc Natl Acad Sci U S A201210928113121131722745173
   PubMed Web of Science ®Google Scholar
• StamosJLWeisWIThe β-catenin destruction complexCold Spring Harb Perspect Biol201351a00789823169527
   PubMed Web of Science ®Google Scholar
• DunXJiangHZouJDifferential expression of DKK-1 binding receptors on stromal cells and myeloma cells results in their distinct response to secreted DKK-1 in myelomaMol Cancer2010924720846389
   PubMed Web of Science ®Google Scholar
• AhnVEChuMLChoiHJTranDAboAWeisWIStructural basis of Wnt signaling inhibition by Dickkopf binding to LRP5/6Dev Cell201121586287322000856
   PubMed Web of Science ®Google Scholar
• JoinerDMKeJZhongZXuHEWilliamsBOLRP5 and LRP6 in development and diseaseTrends Endocrinol Metab2013241313923245947
   PubMed Web of Science ®Google Scholar
• JiangQFTianYWShenQXueHZLiKSENP2 regulated the stability of β-catenin through WWOX in hepatocellular carcinoma cellTumour Biol201435109677968224969559
   PubMedGoogle Scholar
• EbertMFriessHBegerHGBüchlerMWRole of octreotide in the treatment of pancreatic cancerDigestion199455Suppl 148518132137
   PubMedGoogle Scholar
• RosenbergLBarkunANDenisMHPollakMLow dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreasCancer199575123287804972
   PubMed Web of Science ®Google Scholar
• WengerFAJacobiCASiderowAZierenJZierenHUMullerJMHormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifenDer Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen199970669469910427457
   PubMed Web of Science ®Google Scholar
• BurchPABlockMSchroederGPhase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group studyClin Cancer Res2000693486349210999733
   PubMed Web of Science ®Google Scholar
• ButturiniGBettiniRMissiagliaEPredictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinomaEndocr Relat Cancer20061341213122117158766
   PubMed Web of Science ®Google Scholar
• ShojamaneshHGibrilFLouieAProspective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinomaCancer200294233134311900219
   PubMed Web of Science ®Google Scholar
• CascinuSDel FerroECatalanoGA randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapyBr J Cancer1995711971017819058
   PubMed Web of Science ®Google Scholar
• KouroumalisEAOctreotide for cancer of the liver and biliary treeChemotherapy2001472150161
   PubMedGoogle Scholar
• YaoJCGuthrieKAMoranCPhase III prospective randomized comparison trial of depot octreotide plus interferon Alfa-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors: SWOG S0518J Clin Oncol201735151695170328384065
   PubMed Web of Science ®Google Scholar
• RinkeAMüllerHHSchade-BrittingerCPlacebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study GroupJ Clin Oncol200927284656466319704057
   PubMed Web of Science ®Google Scholar
• RinkeAWittenbergMSchade-BrittingerCPlacebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neu-roendocrine midgut tumors (PROMID): results of long-term survivalNeuroendocrinology20171041263226731483
   PubMed Web of Science ®Google Scholar
• ChapmanJACostantinoJPDongBOctreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29Breast Cancer Res Treat2015153235336026276354
   PubMed Web of Science ®Google Scholar
• PavelMEHainsworthJDBaudinEEverolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendo-crine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 studyLancet201137898082005201222119496
   PubMed Web of Science ®Google Scholar
• SoteloJBriceñoELópez-GonzálezMAAdding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trialAnn Intern Med2006144533734316520474
   PubMed Web of Science ®Google Scholar
• RangwalaRChangYCHuJCombined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanomaAutophagy20141081391140224991838
   PubMed Web of Science ®Google Scholar
• GiustinaABonadonnaSBugariGHigh-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trialEur J Endocrinol2009161233133819465485
   PubMed Web of Science ®Google Scholar
• BroderMSBeenhouwerDStrosbergJRNearyMPCherepanovDGastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature reviewWorld J Gastroenterol20152161945195525684964
   PubMed Web of Science ®Google Scholar
• TzekovROcular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlatesDoc Ophthalmol2005110111112016249962
   PubMed Web of Science ®Google Scholar
• SahooSKumarMSinhaVKChloroquine-induced recurrent psychosisAmerican Journal of Therapeutics200714440640717667217
   PubMedGoogle Scholar
• AdebayoRASofoworaGGOnayemiOUdohSJAjayiAAChloroquine-induced pruritus in malaria fever: contribution of malaria parasitaemia and the effects of prednisolone, niacin, and their combination, compared with antihistamineBr J Clin Pharmacol19974421571619278201
   PubMed Web of Science ®Google Scholar
• RustogiAMunshiAJalaliRUnexpected skin reaction induced by radiotherapy after chloroquine useLancet Oncol20067760860916814214
   PubMed Web of Science ®Google Scholar
• TaiDWellsKArcaroliJTargeting the WNT signaling pathway in cancer therapeuticsOncologist201520101189119826306903
   PubMed Web of Science ®Google Scholar
• PaiSGCarneiroBAMotaJMWnt/beta-catenin pathway: modulating anticancer immune responseJ Hematol Oncol201710110128476164
   PubMed Web of Science ®Google Scholar
• ZhanTRindtorffNBoutrosMWnt signaling in cancerOncogene201736111461147327617575
   PubMed Web of Science ®Google Scholar
• KrishnamurthyNKurzrockRTargeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitorsCancer Treat Rev201862506029169144
   PubMed Web of Science ®Google Scholar
• KageyMHHeXRationale for targeting the Wnt signalling modulator Dickkopf-1 for oncologyBr J Pharmacol2017174244637465028574171
   PubMed Web of Science ®Google Scholar
• VokingerKNKesselheimASAvornJSarpatwariAStrategies that delay market entry of generic drugsJAMA Intern Med2017177111665166928975217
   PubMed Web of Science ®Google Scholar
• HuangMShenADingJGengMMolecularly targeted cancer therapy: some lessons from the past decadeTrends Pharmacol Sci2014351415024361003
   PubMed Web of Science ®Google Scholar
• PrintzCFailure rate: Why many cancer drugs don’t receive FDA approval, and what can be done about itCancer2015121101529153025946212
   PubMed Web of Science ®Google Scholar